You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Litigation Details for FEDERAL TRADE COMMISSION v. ABBVIE INC (E.D. Pa. 2014)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in FEDERAL TRADE COMMISSION v. ABBVIE INC
The small molecule drug covered by the patents cited in this case is ⤷  Try a Trial .

Details for FEDERAL TRADE COMMISSION v. ABBVIE INC (E.D. Pa. 2014)

Date Filed Document No. Description Snippet Link To Document
2014-09-08 1 pharmaceutical composition patent relating to AndroGel, U.S. Patent No. 6,503,894 (the “’894 Patent”). To obtain this… this patent, Unimed and Besins were required by the U.S. Patent and Trademark Offlce (“PTO”) to significantly…. Aware of the patent’s narrow scope, Perrigo and Teva designed around the ’894 Patent, developing generic…while prosecuting the ’894 Patent before the PTO in order to obtain the ’894 Patent. Abeie Defendants and …their products infringe the ’894 Patent is without merit. ln the patent litigation, Teva counterclaimed External link to document
2015-08-25 118 7 Besins together hold U.S. Patent No. 6,503,894 (the “‘894 Patent”) for a popular brand-name testosterone…infringe GSK’s patent or that the patent was unenforceable. GSK responded by filing patent infringement…of the patent. The FTC alleges that Abbott, Unimed, and Besins initiated sham patent infringement…up its patent challenge by offering an early entry date for AndroGel, the subject of the patent litigation…the extent it was based on the settlement of the patent litigation. The External link to document
2015-12-13 145 Memorandum and/or Opinion Unimed”) and Besins obtained U.S. Patent No. 6,503,894 (“the ‘894 patent”) for the brand-name testosterone…referenced by name in the ‘894 patent. We do not opine on whether or not the ‘894 patent covers additional penetration…recent meeting with patent examiner and examiner’s decision regarding allowing patent.” The email was…a United States Patent and Trademark Office examiner to Mahoney concerning the patent application. …its patent claims were narrowed to a single penetration enhancer at the time it filed the patent infringement External link to document
2016-08-25 220 Memorandum and/or Opinion LLC (“Unimed”) and Besins obtained U.S. Patent Number 6,503,894 has withdrawn claims of privilege in…that the AbbVie defendants and Besins filed sham patent infringement actions against Teva and Perrigo …entered into an anticompetitive settlement of that patent litigation. In January 2003, Unimed …Document 220 Filed 08/25/16 Page 3 of 35 (“the ‘894 patent”) for the brand-name testosterone drug, AndroGel…2011 and October 2011, AbbVie and Besins filed patent infringement lawsuits against Teva and Perrigo External link to document
2017-09-15 300 Memorandum and/or Opinion testosterone and is protected by U.S. Patent No. 6,503,894 (“the ‘894 patent”). The FTC further alleges …history record of the ‘894 patent, which issued on January 7, 2003 from U.S. Patent Application Serial No.… 1%. In June 2001, the patent examiner at the U.S. Patent and Trademark Office (“PTO”) rejected…surrendered the equivalents for reasons of patentability during the patent prosecution process. See Festo …narrowing the scope of the patent application in order to expedite the patent prosecution process is necessarily External link to document
2017-12-05 319 Pretrial Memorandum As patent co-owners, Defendants knew they had secured allowance of U.S. Patent No. 6,503,894 (the …individually, assert a patent infringement claim that U.S. Patent No. 6,503,894 is infringed by…royalty- free license for U.S. Patent Nos. 6,503,894; 8,466,136; 8,466,137; 8,466,138; 8,486,…300 at 23.) After an interview with the patent examiner, patent prosecution counsel, Joseph Mahoney, explicitly…infringe the ’894 patent because it used a different penetration enhancer than the patented composition. External link to document
2014-11-12 37 amounts—U.S. Patent No. 6,503,894 (the “’894 patent”). Id. ¶¶ 45, 58. The ’894 patent covers testosterone… 2. Patent Certifications And Patent Litigation Under Hatch-Waxman ....…hundreds of millions of dollars from the patent holder to the patent challenger. The alleged “reverse payment…recognizes the patent rights (including exclusivity) of brand manufacturers by permitting early patent challenges…17 of 51 2. Patent Certifications And Patent Litigation Under Hatch-Waxman External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.